First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.03 ...

India had refused accept demands from the UK and Switzerland for data exclusivity to protect generic pharma industry, with ...

Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

The FDA has accepted GSK’s application for priority review of gepotidacin, a first-in-class antibiotic for uncomplicated ...

The FTSE 100 achieved a new closing high on Wednesday but eased on Thursday morning, with some of its bigger constituents going ex-dividend. Shares in miner Rio Tinto fell 3.4%, GSK lost 1.9%, BP fell ...

FTSE 100 Thursday GDP surprises after June surgeAviva hails strong performanceCentrica buys Grain LNG facility ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

The biggest risers on the FTSE 100 were Spirax, up 240.00 pence at 7,085.00p, AstraZeneca, up 336.00 pence at 11,422.00p, GSK ...